- Conditions
- Clear-cell Metastatic Renal Cell Carcinoma
- Interventions
- Everolimus, MLN0128, MLN1117
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Venice, Florida • West Palm Beach, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Not listed
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 40 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Long Beach, California • Miami, Florida + 4 more
- Conditions
- Hypertension
- Interventions
- Nebivolol, Metoprolol succinate
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Aging, Exercise, Cardiovascular Disease
- Interventions
- Exercise Training, Exercise Cessation
- Other
- Lead sponsor
- Baltimore VA Medical Center
- Federal
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Fuchs' Endothelial Dystrophy
- Interventions
- Ripasudil hydrochloride hydrate 0.4% ophthalmic solution
- Drug
- Lead sponsor
- Marian Macsai, MD
- Other
- Eligibility
- 18 Years to 91 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Glenview, Illinois
- Conditions
- Renal Cell Carcinoma
- Interventions
- Everolimus, GDC-0980
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 8
- States / cities
- Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 5 more
- Conditions
- Cardiovascular Disease
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Rheumatoid Arthritis
- Interventions
- Not listed
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2020
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
- Interventions
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel, Topotecan
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Anchorage, Alaska • Los Angeles, California • Clermont, Florida + 15 more
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Glioblastoma
- Interventions
- Not listed
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection)
- Device · Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 52
- States / cities
- Mesa, Arizona • Bakersfield, California • Huntington Beach, California + 47 more
- Conditions
- HIV, Endothelial Dysfunction, Inflammation, Insulin Resistance
- Interventions
- Salsalate
- Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Renal Cell Carcinoma, Kidney Cancer
- Interventions
- Capecitabine, Gemcitabine, Bevacizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Coronary Arteriosclerosis
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pre-Eclampsia, Vascular Diseases
- Interventions
- Omental Biopsy
- Procedure
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 166 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Coronary Artery Disease
- Interventions
- Clopidogrel, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
- Interventions
- Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 15
- States / cities
- Laguna Hills, California • Lancaster, California • Cape Coral, Florida + 11 more
- Conditions
- Endothelial Dysfunction
- Interventions
- darapladib, placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Endothelial Cells, Exercise Tolerance
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Pumitamig, Atezolizumab, Etoposide, Carboplatin (or cisplatin if carboplatin is not tolerated)
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 621 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Clermont, Florida • Palm Bay, Florida + 29 more
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Interventions
- Ramucirumab, MEDI4736
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 7
- States / cities
- Santa Monica, California • Baltimore, Maryland • St Louis, Missouri + 4 more
- Conditions
- Graft-Versus-Host Disease
- Interventions
- Filgrastim
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hypertension
- Interventions
- DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography
- Drug · Procedure
- Lead sponsor
- Wanpen Vongpatanasin
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Endothelial Dysfunction
- Interventions
- Aliskiren, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota